Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

1. Clinical Objective : To improve the growth of these children

2. Genetic objective : A study of the genetics of the syndrome

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Children and adolescents with Noonan's syndrome with a height < -2 SD and no progressive cardiopathy

Exclusion Criteria:

• Age < 3 years

• Height ≥ -2 SD

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.